Overview

A Single-center Clinical Study to Evaluate the Safety, Tolerability, and Efficacy of LCAR-L10D Cell Formulations Targeting CD19 and CD22 in Patients With CD19- and/or CD22-Positive Relapsed/Refractory B-cell Lymphoma

Status:
Terminated

Trial end date:
2021-05-01

Target enrollment:

Participant gender:

Summary

This is a prospective, single-arm, single-center, open-label, single-dose dose finding and expansion study to evaluate the safety, tolerability, pharmacokinetics, and anti-tumor efficacy profile of LCAR-L10D in subjects with CD19- and/or CD22-positive relapsed/refractory B-cell lymphoma after prior adequate standard of care.

Phase:

Phase 1

Details

Lead Sponsor:

Second Affiliated Hospital of Xi'an Jiaotong University

Collaborator:

Nanjing Legend Biotech Co.